Australian Government
Department of Health and Aged Care
Office of the Gene Technology Regulator

28 August 2024

Notification of decision on application DIR 202 from Intervet Australia Pty Ltd for the commercial supply of a live attenuated vaccine containing canine distemper virus and genetically modified canine parvovirus (Nobivac Puppy DP Plus) for dogs

The Regulator has issued licence DIR 202 to Intervet Australia Pty Ltd, authorising the commercial supply of a vaccine containing genetically modified canine parvovirus to protect dogs against canine parvovirus.

The release is authorised to take place throughout Australia when prescribed by a registered veterinarian.

The Risk Assessment and Risk Management Plan (RARMP) and the licence were finalised taking into account input received during consultation with the public, State and Territory governments, Australian Government agencies, the Minister for the Environment, the Gene Technology Technical Advisory Committee and local councils. The Regulator thanks submitters for their contributions.

Submissions are summarised in Appendix B of the RARMP, together with information about how the issues raised relating to risks to human health and safety or the environment were considered in finalising the RARMP.

The finalised RARMP concludes that this commercial release poses negligible risks to people and the environment and imposes specific risk treatment measures to maintain the context of the risk assessment. Additionally, general licence conditions have also been imposed to ensure ongoing oversight of the release.

The finalised RARMP, a summary of the RARMP, the licence and Questions and Answers about this decision can be obtained online from the DIR-202 page of the Office of the Gene Technology Regulator's (OGTR) website or requested via the contacts detailed below.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601 Tel: 1800 181 030 E-mail: ogtr@health.gov.au
OGTR website